Lab Publications

Pathogenicity of human antibodies against myelin oligodendrocyte glycoprotein

Ann Neurol 2018;84:315–328

Autoantibodies against myelin oligodendrocyte glycoprotein (MOG) can be detected in the blood of a proportion of patients with inflammatory demyelinating diseases of the CNS. We affinity-purified MOG-Abs from the blood of two patients. The Abs recognized different epitopes on MOG. The anti-MOG Abs from the patients were pathogenic upon transfer into rats and we could dissect two different mechanisms by which these MOG-Abs enhanced pathology. First, together with cognate MOG-specific T cells, these Abs enhanced T cell infiltration; Second, together with MBP-specific T cells that strongly breach the blood-brain barrier, these MOG-Abs induced demyelination associated with deposition of C9neo, resembling a multiple sclerosis type II pathology. This suggests that MOG-Abs are similarly pathogenic in patients. [more...]
 

Features of Human CD3+CD20+ T Cells.

J Immunol. 2016 Aug 15;197(4):1111-7. doi: 10.4049/jimmunol.1600089.

 

Autoantibodies to MOG in a distinct subgroup of adult multiple sclerosis.

Neurol Neuroimmunol Neuroinflamm. 2016 Jun 30;3(5):e257. doi: 10.1212/NXI.0000000000000257.

 

Fingolimod induces neuroprotective factors in human astrocytes

J Neuroinflammation. 2015 Sep 30;12:184. doi: 10.1186/s12974-015-0393-6.

Fingolimod is the first sphingosine-1-phosphate receptor modulator approved for the treatment of multiple sclerosis. It reduces brain atrophy and neuroprotective effects are hypothesized. We identified effects of fingolimod on astrocytes, namely induction of neurotrophic mediators (LIF, HBEGF, and IL11) and inhibition of TNF-induced inflammatory genes (CXCL10, BAFF, MX1, and OAS2). This supports the view that a part of the effects of fingolimod may be mediated via astrocytes. [more...]
 

γ-secretase directly sheds the survival receptor BCMA from plasma cells

Nat. Commun. 6:7333 doi: 10.1038/ncomms8333

Plasma cells produce antibodies that inactivate pathogens, but may also cause autoimmune diseases. Therefore a balanced regulation of plasma cells is essential. We found that the lifespan of plasma cells is regulated through shedding of their survival receptor BCMA by γ-secretase. The released part of BCMA reflects the antibody production by plasma cells in the brain of MS patients. Please find the press release here: [more...]
 

Histopathology and clinical course of MOG-antibody-associated encephalomyelitis.

Ann Clin Transl Neurol. 2015 Mar;2(3):295-301. doi: 10.1002/acn3.164.

 

The Immunoregulator Soluble TACI Is Released by ADAM10 and Reflects B Cell Activation in Autoimmunity

J Immunol. 2015 Jan 15;194(2):542-52. doi: 10.4049/jimmunol.1402070.

The cytokines BAFF and APRIL regulate B cell survival and activation. In this study we identify a soluble form of the BAFF/APRIL receptor TACI that is present in blood and CSF. Soluble TACI acts as a decoy receptor for its ligands and may serve as a useful biomarker for the optimization of therapeutic approaches targeting the BAFF/APRIL system. [more...]
 

B cells in Multiple Sclerosis: Good or bad guys?

Eur. J. Immunol. 2014. 44: 1247–1250, an article for 28 May 2014 - World MS Day 2014

Review related to the World MS Day 2014. A pathogenic role of B cells in MS is indicated by the success of B-cell depleting therapy with anti-CD20 mAbs. Unexpectedly, however, targeting of survival factors for B cells by atacicept worsened MS. In this review, we discuss pro- and anti-inflammatory features of B cells. [more...]
 

IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases

The Meinl group contributed to a very recent paper published in Nature. This paper shows that B cells down-regulate inflammation via production of the cytokine IL-35. [more...]
 

Multiple sclerosis: An old drug plays a new trick

Nature. 2013 Oct 9. doi: 10.1038/nature12694

In this News & Views article we present an advance towards repair of multiple sclerosis lesions. [more...]
 

Distinction and temporal stability of conformational epitopes on myelin oligodendrocyte glycoprotein recognized by patients with different inflammatory central nervous system diseases

J Immunol. 2013 Oct 1;191(7):3594-604. doi: 10.4049/jimmunol.1301296

Autoantibodies targeting myelin oligodendrocyte glycoprotein (MOG) are found in different inflammatory diseases of the CNS. Here we distinguish different conformational epitopes of MOG. [more...]
 

The utility of cerebrospinal fluid analysis in patients with multiple sclerosis

Nat Rev Neurol. 2013 May;9(5):267-76. doi: 10.1038/nrneurol.2013.41

Alterations of the cerebrospinal fluid are commonly found in multiple sclerosis. This review presents the utility of cerebrospinal fluid analysis for diagnosis, its impact on our understanding of the pathophysiology and therapy mechanisms, as well as for monitoring inflammatory and neurodegenerative processes. [more...]
 

B cells and antibodies in multiple sclerosis pathogenesis and therapy

Nat Rev Neurol. 2012 Oct 9. doi: 10.1038/nrneurol.2012.203

In diesem Übersichtsartikel beschreiben wir wie das Milieu im ZNS von MS Patienten das Überleben von B-Lymphozyten fördert und diskutieren mögliche Zielstrukturen für Autoantikörper von MS Patienten. Therapeutische Strategien, die B-Lymphozyten direkt entfernen oder einen Effekt auf diese Immunzelltypen haben, werden vorgestellt. [more...]
 
 
DE

Director

Prof. Dr.

Reinhard Hohlfeld

Contact  


Prof. Dr.

Martin Kerschensteiner

Contact  

Group Leader

Prof. Dr.

Edgar Meinl

Contact 

Important links